How to generate an anticancer immune response in multiple myeloma
Lessening the economic burden of treating CLL
The success story of indolent disease treatment expanded to difficult-to-treat patient groups
Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
Upcoming CLL trials on treatment options